In recent years, patients are expecting more targeted, effective and personalized therapies and New Science requires technology to become an integral part of the patient treatment. In addition, agility and responsiveness are more critical for life sciences companies than ever before. For all the tremendous success with the vaccine development, the COVID-19 pandemic has brought new complexity to supply chain and patient engagement models. The industry needs to scale its digital capabilities to address fluctuations in demand and improve resilience across its core operations.

In order to do so, life sciences CIOs have the opportunity to reimagine their technology architectures and extend their ecosystem of partners to disrupt the way they deliver improved outcomes for patients.

Our life sciences technology practice helps navigate this everchanging technology landscape by identifying opportunities for significant capability advances with our enterprise advisory, platform, cloud, data and analytics services.

The life sciences industry is on the threshold of a new decade of digital transformation, and at a defining moment for all leaders. The Metaverse Continuum will transform how businesses interact with customers and how work is done. Our two surveys of biopharma and medical technology executives confirms this: 

• 91% of MedTech executives believe the metaverse will have a positive impact on their organizations.
• 42% of biopharma executives believe the metaverse will have a breakthrough or transformational impact on their organizations.

The Metaverse Continuum incorporates all digitally enhanced realities—both social and business-related. It touches all patients, healthcare professionals and enterprises – from reality to virtual and back.

This year’s Accenture Technology Vision explores four trends that reveal how new technology innovations like metaverse are reshaping biopharma and medical technology experiences of the future.